Sinopharm Group Le-Ren-Tang Medicines Co Ltd, or Sinopharm Group Le-Ren-Tang, was established in April 2011. It is a large pharmaceutical commercial enterprise jointly invested by Sinopharm Group Co Ltd (Sinopharm Holding) and Le-Ren-Tang Investment Group Co Ltd. 

With a registered capital of 175 million yuan ($24.51 million), it focuses on pharmaceutical logistics and distribution, and is the first business in Hebei province to obtain Good Supply Practice (GSP) and ISO9000 certifications. 

In 2022, Sinopharm Group Le-Ren-Tang’s sales revenue reached 29.3 billion yuan, making it a management platform and leading enterprise of Sinopharm Holding in Hebei. In 2020, it was honored with the title of sixth "National Model Unit". 

Throughout its history, Sinopharm Group Le-Ren-Tang, under the leadership of the CPC Sinopharm committee, the CPC Sinopharm Holding committee and the Shijiazhuang State-owned Assets Supervision and Administration Commission, has closely aligned with the nation’s 14th Five-Year Plan.

Adhering to its corporate philosophy of "all for health, health for all, spreading love, and benefiting the people," Sinopharm Group Le-Ren-Tang has effectively fulfilled its social responsibilities. During the COVID-19 pandemic, it made every effort to ensure the supply of medicines and medical devices, safeguarding public health and demonstrating the responsibility of a central Stated-owned enterprise.

Simultaneously, the enterprise has continuously improved the construction of its spiritual civilization, enhanced the comprehensive quality of its employees, established a positive image for cadres and employees, and gradually strengthened its brand influence.

With significant improvement in Sinopharm Group Le-Ren-Tang’s comprehensive strength, it has consistently been recognized as a model unit in Shijiazhuang city and Hebei province.